Patents Issued in July 16, 2020
  • Publication number: 20200224172
    Abstract: Methods and compositions for producing induced pluripotent stem cell by introducing nucleic acids encoding one or more transcription factors including Obox6 into a target cell.
    Type: Application
    Filed: September 19, 2018
    Publication date: July 16, 2020
    Inventors: Geoffrey Schiebinger, Jian Shu, Marcin Tabaka, Brian Cleary, Aviv Regev, Eric S. Lander, Philippe Rigollet
  • Publication number: 20200224173
    Abstract: Provided herein are methods of improving rAAV production in cells, the method comprising increasing the salt concentration in the media in which the cells are infected or transfected, cultured, or in which they produce AAV. Aspects of the disclosure relate to improved methods of rAAV production by co-infecting suspension adapted cells (e.g., suspension adapted HEK293 cells) with viruses that encode one or more AAV components for producing rAAV particles within the suspension adapted cells.
    Type: Application
    Filed: December 23, 2016
    Publication date: July 16, 2020
    Applicant: University of Florida Research Foundation, Incorporated
    Inventors: Nathalie Clement, Barry John Byme, Laura A. Small
  • Publication number: 20200224174
    Abstract: The disclosure provides methods for an in vitro evolution technique to identify and characterize mutations in the non-structural genes of an alphavirus replicon that increase the strength and persistence of expression of the replicon genome. Also provided herein are in vivo methods for administering to an animal model a mutated alphavirus replicon that codes for a gene of experimental or therapeutic interest in the subgenome of the alphavirus replicon. The mutations identified herein improve the therapeutic potential of self-replicating RNA, which may have implications for cancer immunotherapy and beyond, e.g., for vaccination or gene therapy.
    Type: Application
    Filed: January 10, 2020
    Publication date: July 16, 2020
    Applicant: Massachusetts Institute of Technology
    Inventors: Darrell J. Irvine, Ron Weiss, Yingzhong Li
  • Publication number: 20200224175
    Abstract: This document relates to methods and materials for virotherapy. For example, this document provides methods and materials for treating cancer using a recombinant mumps virus as an oncolytic agent.
    Type: Application
    Filed: January 21, 2020
    Publication date: July 16, 2020
    Applicant: Mayo Foundation for Medical Education and Research
    Inventors: Mark J. Federspiel, Arun Ammayappan, Gennett Pike, Stephen James Russell
  • Publication number: 20200224176
    Abstract: Described are nicotine-degrading enzyme variants that exhibit increased nicotine-degrading activity and/or decreased immunogenicity relative to the wild-type NicA2 and NOX enzymes, compositions comprising the variants, and methods using them.
    Type: Application
    Filed: February 2, 2018
    Publication date: July 16, 2020
    Applicants: ANTIDOTE THERAPEUTICS, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Matthew W. KALNIK, Thomas THISTED, Everett STONE, Charles C. REED, Max RODNICK-SMITH
  • Publication number: 20200224177
    Abstract: The present invention provides a stable cell line overexpressing a recombinant vitamin K-dependent (VKD) protein and both a recombinant vitamin K epoxide reductase (VKOR) and a recombinant vitamin K dependent gamma carboxylase (VKGC), wherein the amount of fully carboxylated VKD protein produced in the cell is increased 10% as compared to the amount of fully carboxylated VKD protein produced in the cell in the absence of the recombinant VKOR and the recombinant VKGC.
    Type: Application
    Filed: August 27, 2019
    Publication date: July 16, 2020
    Inventors: Darrel W. Stafford, Tao Li
  • Publication number: 20200224178
    Abstract: An enzyme having the following characteristics of (a) and (b): (a) the enzyme has an activity of reversible dehydrogenation of D-amino acid; and (b) the enzyme is a hexamer of polypeptides having an amino acid sequence that has 80% or more identity with an amino acid sequence of SEQ ID NO: 2.
    Type: Application
    Filed: August 9, 2018
    Publication date: July 16, 2020
    Applicants: Kureha Corporation, National Institute Of Advanced Industrial Science And Technology
    Inventors: Hironaga AKITA, Yuusuke NAKAMICHI, Masahiro WATANABE, Akinori MATSUSHIKA, Tomotake MORITA
  • Publication number: 20200224179
    Abstract: A protease with a function of degrading carotenoids of scallop is provided, which belongs to the technical field of genetic engineering. In particular, the present invention relates to the sequence and application of a carotenoid oxidase gene of scallop. The present invention analyzes the gene sequence, and verifies that the gene has function of degrading carotenoids of scallop scallop by RNA interference technology, and can be used to increase the carotenoid content of the scallop muscle of scallop scallop. The gene verified that the gene expression products can degrade carotenoids accumulated in bacteria. In addition, the RNA interference method provides a powerful tool for the study of scallop functional genes; the prokaryotic expression and protein purification methods provided can efficiently prepare oxidative lyases of carotenoid in scallop, so as to provide necessary experimental tools for in-depth research of the mechanism of shell carotene metabolism.
    Type: Application
    Filed: March 25, 2020
    Publication date: July 16, 2020
    Inventors: Xiaoli Hu, Zhenmin Bao, Huizhen Wang, Shuyue Wang, Xue Li, Liang Zhao, Mengran Zhang, Shanshan Lian, Tingting Li, Wei Wu, Shi Wang, Shiqi Liu, Lingling Zhang, Wei Lu
  • Publication number: 20200224180
    Abstract: The present invention relates to a recombinant host comprising a recombinant nucleic acid sequence encoding a polypeptide having at least about: a. 85% identity to the amino acid sequence set forth in SEQ ID NO: 1; b. 85% identity to the amino acid sequence set forth in SEQ ID NO: 3; c. 85% identity to the amino acid sequence set forth in SEQ ID NO: 6; d. 85% identity to the amino acid sequence set forth in SEQ ID NO: 9; e. 85% identity to the amino acid sequence set forth in SEQ ID NO: 11; f. 85% identity to the amino acid sequence set forth in SEQ ID NO: 14; g. 85% identity to the amino acid sequence set forth in SEQ ID NO: 17; h. 85% identity to the amino acid sequence set forth in SEQ ID NO: 20; i. 85% identity to the amino acid sequence set forth in SEQ ID NO: 22; or j. 85% identity to the amino acid sequence set forth in SEQ ID NO: 25.
    Type: Application
    Filed: January 30, 2020
    Publication date: July 16, 2020
    Inventors: Viktor Marius BOER, Johannes Gustaaf Emst VAN LEEUWEN, Priscilla ZWARTJENS, Catharina Petronella Antonia Maria KOLEN
  • Publication number: 20200224181
    Abstract: The invention relates to mutant DNA polymerases of the Pol theta subfamily capable of performing non-templated nucleic acid extension, or of a functional fragment of such a polymerase, methods of producing these mutant DNA polymerases, kits and methods of using these mutant DNA polymerases.
    Type: Application
    Filed: September 20, 2018
    Publication date: July 16, 2020
    Inventors: Marc DELARUE, Volahasina (Irina) RANDRIANJATOVO GBALOU
  • Publication number: 20200224182
    Abstract: The disclosure provides a method of producing recombinant alkaline phosphatase comprising: (i) culturing an alkaline phosphatase in a recombinant cell culture; (ii) obtaining a preparation of recombinant alkaline phosphatase from the cell culture; and (iii) minimizing in the preparation a concentration of at least one metal ion selected from the group consisting of: Nickel (Ni), Cobalt (Co), Copper (Cu), Manganese (Mn), Chromium (Cr), and Molybdenum (Mo).
    Type: Application
    Filed: June 6, 2017
    Publication date: July 16, 2020
    Inventors: Saravanamoorthy RAJENDRAN, Rachael ALFORD, Sean GALLAGHER, Anne KANTARDJIEFF, Jared DAVIS
  • Publication number: 20200224183
    Abstract: An acid phosphatase mutant, and method for preparing nicotinamide riboside by same. The mutant is a protein of the following (a), (b) or (c): (a) a protein, having an amino acid sequence shown in SEQ ID NO: 3; (b) a protein, derived from (a), having catalytic activity higher than an acid phosphatase parent having an amino acid sequence shown in SEQ ID NO: 2, obtained by substituting, deleting or adding several amino acids in the amino acid sequence shown in SEQ ID NO: 3, using nicotinamide mononucleotide as a substrate; (c) a protein, having catalytic activity higher than the acid phosphatase shown in SEQ ID NO: 2, having 90% or more homology with the amino acid sequence of the protein defined by (a) or (b), and using nicotinamide mononucleotide as a substrate. It is used to prepare nicotinamide riboside and the conversion rate can be 99%.
    Type: Application
    Filed: August 17, 2018
    Publication date: July 16, 2020
    Inventors: Rongzhao FU, Zhenwei LI, Min WANG, Xinglin GUO
  • Publication number: 20200224184
    Abstract: The present disclosure provides for compositions comprising a chimeric polypeptide comprising a polypeptide effective for treating glycogen storage disease and an internalizing moiety that promotes delivery into cells. In certain embodiments, the polypeptide effective for treating glycogen storage disease is an acid alpha-glucosidase (GAA), a laforin, an amyloglucosidase (AGL), a malin, or an alpha amylase. The present disclosure also provides for methods for decreasing glycogen accumulation in cells or for treating glycogen storage diseases, including Forbes-Cori Disease, Andersen Disease, von Gierke Disease, Pompe Disease, and Lafora Disease, comprising administering the chimeric polypeptide disclosed herein.
    Type: Application
    Filed: February 11, 2019
    Publication date: July 16, 2020
    Inventor: Dustin D. Armstrong
  • Publication number: 20200224185
    Abstract: Provided herein are Clostridial Botulinum neurotoxin (BoNT) polypeptides of a novel serotype (BoNT/X) and methods of making and using the BoNT polypeptides, e.g., in therapeutic applications.
    Type: Application
    Filed: July 7, 2017
    Publication date: July 16, 2020
    Applicant: Children's Medical Center Corporation
    Inventors: Min Dong, Sicai Zhang, Paul Stenmark
  • Publication number: 20200224186
    Abstract: The application discloses multimeric assemblies including multiple oligomeric substructures, where each oligomeric substructure includes multiple proteins that self-interact around at least one axis of rotational symmetry, where each protein includes one or more polypeptide-polypeptide interface (“O interface”); and one or more polypeptide domain that is capable of effecting membrane scission and release of an enveloped multimeric assembly from a cell by recruiting the ESCRT machinery to the site of budding by binding to one or more proteins in the eukaryotic ESCRT complex (“L domain”); and where the multimeric assembly includes one or more subunits comprising one or more polypeptide domain that is capable of interacting with a lipid bilayer (“M domain”), as well as membrane-enveloped versions of the multimeric assemblies.
    Type: Application
    Filed: November 6, 2019
    Publication date: July 16, 2020
    Inventors: Neil KING, Wesley SUNDQUIST, Joerg VOTTELER, Yang HSIA, David BAKER, Jacob BALE, Marc LAJOIE, Gabriel BUTTERFIELD, Elizabeth GRAY, Daniel STETSON
  • Publication number: 20200224187
    Abstract: The present invention relates to polypeptide, preferably to a glucose isomerase, comprising an amino acid sequence, wherein the amino acid sequence of the polypeptide, preferably the glucose isomerase, is at least 95% identical to an amino acid sequence of SEQ ID NO:1, wherein the amino acid sequence of the polypeptide, preferably the glucose isomerase, comprises an amino acid substitution at one or more amino acid positions, wherein the one or more amino acid positions is/are each and independently selected from the group consisting of SEQ ID NO: 1 amino acid positions 89, 90, 95, 0, 33, 34, 35, and 59. The present invention further relates to methods preparing glucose including the use of the polypeptides of the invention for preparing glucose.
    Type: Application
    Filed: May 4, 2018
    Publication date: July 16, 2020
    Inventors: Birgit Brucher, Andreas Vogel, Hanna Maria Dudek, Rico Czaja
  • Publication number: 20200224188
    Abstract: A well for electrically stimulating at least one cell. The well includes a bottom portion and comprises an adaptive electrode arrangement for introducing an electric field into the well. The adaptive electrode arrangement includes a pair of electrodes disposed within the well. Each electrode of the pair of electrodes has a distal end and is independently and axially displaceable relative to the other electrode and the bottom portion of the well. The distal end of each electrode of the pair of electrodes is in contact with the bottom portion of the well, ensuring a uniform and constant electric field is applied within the well.
    Type: Application
    Filed: August 7, 2018
    Publication date: July 16, 2020
    Inventors: Chuck Z. Li, Brandon Zachary Sarich, Phillip Ng
  • Publication number: 20200224189
    Abstract: Provided is a composition for preserving cell-free nucleic acids and/or cells in a biological sample and methods for use thereof. The composition comprises at least one volume excluding polymer, at least one osmotic agent and at least one enzyme inhibitor. The composition optionally further comprises at least one metabolic inhibitor. Further, provided is a kit comprising the composition, preferably in a blood collection tube, or the components of the composition.
    Type: Application
    Filed: May 16, 2017
    Publication date: July 16, 2020
    Applicant: Norgen Biotek Corp.
    Inventors: Taha Alexander HAJ-AHMAD, Yousef HAJ-AHMAD
  • Publication number: 20200224190
    Abstract: The present disclosure provides methods for selectively tagging 5-methylcytosine in a DNA sample and using this approach for genome-wide profiling of 5-methylcytosine in a low input DNA sample such as circulating cell-free DNA.
    Type: Application
    Filed: September 11, 2018
    Publication date: July 16, 2020
    Inventors: Chunxiao Song, Paulina Siejka
  • Publication number: 20200224191
    Abstract: The present disclosure provides synthetic modular polypeptide libraries and nucleic acids encoding such synthetic modular polypeptide libraries. Also provided are methods of making synthetic modular polypeptide libraries and nucleic acids encoding synthetic modular polypeptide libraries. Methods of screening a synthetic modular polypeptide library to identify a selected phenotype associated with a member of a synthetic modular polypeptide library are also provided where such methods find use in both in vitro and in vivo assays.
    Type: Application
    Filed: August 31, 2016
    Publication date: July 16, 2020
    Inventors: Wendell A. Lim, Scott M. Coyle, Russell M. Gordley, Kole T. Roybal
  • Publication number: 20200224192
    Abstract: Provided are a method and a kit for constructing a simplified genomic library. The method comprises: performing a non-specific amplification on a whole genome with a first pair of primers to obtain random amplified fragments; performing a specific amplification on the random amplified fragments with a second pair of primers to obtain the simplified genomic library.
    Type: Application
    Filed: January 26, 2018
    Publication date: July 16, 2020
    Inventors: Kejian WANG, Qing LIU
  • Publication number: 20200224193
    Abstract: The present invention relates to a method of manufacturing vesicles by delivery of RNA nanoparticles, in which messenger RNA nanoparticles for target protein expression are delivered to a cell, and vesicles manufactured using the same. A protein is locally over-expressed in the cell to thus be excreted through the vesicles to the outside of the cell, which enables the vesicles containing a target protein to be easily mass-produced. The vesicles containing the target protein is obtained regardless of the cell type. The concentration of the messenger RNA nanoparticles delivered to the cell is adjusted, thus adjusting the manufacturing amount and the manufacturing time of the vesicles. After the surface of the cell is reformed, the messenger RNA nanoparticles are delivered thereto, thus obtaining the vesicles carrying the target protein and having a surface property of a specific function.
    Type: Application
    Filed: October 8, 2019
    Publication date: July 16, 2020
    Inventors: Jong-Bum LEE, Hye-Jin Kim
  • Publication number: 20200224194
    Abstract: Nucleic acid expression systems are provided herein that include a first synthetic oligonucleotide comprising a payload sequence and a second synthetic oligonucleotide comprising a sequence that encodes a helper polypeptide. Compositions (e.g., pharmaceutical compositions) comprising the nucleic acid expression systems as well as methods of using the same are also provided herein.
    Type: Application
    Filed: September 20, 2018
    Publication date: July 16, 2020
    Inventors: Nikolai Eroshenko, Nikhil Dhar, Taylor Gill, Marianna Keaveney, Hannu Rajaniemi
  • Publication number: 20200224195
    Abstract: An agent capable of decreasing the activity of FAM46A for use in supporting weight maintenance and/or treating or preventing obesity.
    Type: Application
    Filed: November 29, 2017
    Publication date: July 16, 2020
    Inventors: Jerome Carayol, Armand Valesia, Jorg Hager
  • Publication number: 20200224196
    Abstract: The invention provides a single-stranded oligonucleotide represented by the formula [Xz-Lx]m-X-Y-[Ly-Yz]n, wherein X is represented by Xa-Xb, Xa is coupled with Y, and Xb and Y hybridize. Xa is composed of 1 to 40 nucleotides and contains at least one modified-nucleotide. Xb is composed of 4 to 40 nucleotides and contains at least one modified-nucleotide. Y is composed of 4 to 40 nucleotides and contains at least one ribonucleotide. Xz and Yz are composed of 5 to 40 nucleotides and contain at least one modified-nucleotide. Nucleotide sequences X, Xz and Yz have an antisense sequence capable of hybridizing with a target RNA. Lx and Ly are composed of 0 to 20 nucleotides.
    Type: Application
    Filed: July 26, 2018
    Publication date: July 16, 2020
    Applicant: NISSAN CHEMICAL CORPORATION
    Inventors: Yusuke IRIYAMA, Hiroyuki NAKAJIMA, Tatsuro KANAKI
  • Publication number: 20200224197
    Abstract: There is disclosed a trans-acting functional nucleic acid molecule comprising a eukaryotic target binding sequence comprising a sequence reverse complementary to a target mRNA sequence for which protein translation is to be enhanced, and a regulatory sequence comprising an internal ribosome entry site (IRES) sequence or an internal ribosome entry site (IRES) derived sequence and enhancing translation of the target mRNA sequence, wherein the regulatory sequence is located 3? of the target binding sequence.
    Type: Application
    Filed: September 20, 2018
    Publication date: July 16, 2020
    Applicants: FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA, SCUOLA INTERNAZIONALE SUPERIORE DI STUDI AVANZATI
    Inventors: Stefano GUSTINCICH, Silvia ZUCCHELLI
  • Publication number: 20200224198
    Abstract: Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.
    Type: Application
    Filed: March 2, 2020
    Publication date: July 16, 2020
    Applicant: IONIS PHARMACEUTICALS, INC.
    Inventors: Thazha P. PRAKASH, Punit P. SETH, Eric E. SWAYZE
  • Publication number: 20200224199
    Abstract: Described herein are small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, and methods of use of the small molecule splicing modulator compounds for modulating splicing and treating diseases and conditions.
    Type: Application
    Filed: March 13, 2020
    Publication date: July 16, 2020
    Inventors: Michael Luzzio, Kathleen Mccarthy, William Haney
  • Publication number: 20200224200
    Abstract: Embodiments of the disclosure relate to modulation of an immune response comprising modulating the interaction between a death associated protein kinase (DAPK) and stimulator of interferon genes protein (STING) pathway. In certain embodiments, a method is provided for treating a subject for an inflammatory or autoimmune disease, or cancer, or a side effect or symptom thereof by administering an agent that modulates the interaction between a DAPK and the STING pathway.
    Type: Application
    Filed: September 25, 2018
    Publication date: July 16, 2020
    Inventors: Sonia SHARMA, Mariko TAKAHASHI
  • Publication number: 20200224201
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting epression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.
    Type: Application
    Filed: December 12, 2019
    Publication date: July 16, 2020
    Inventors: William Querbes, Kevin Fitzgerald, James Butler, Stephanie Williams, Gregory Hinkle, Martin A. Maier
  • Publication number: 20200224202
    Abstract: The present invention refers to immunosuppression-reverting oligonucleotides comprising 12 to 18 nucleotides, wherein at least one of the nucleotides is modified, and the oligonucleotide hybridizes with a nucleic acid sequence of an ectonucleotidase (NTPdase; CD73) of SEQ ID NO.1 (human), wherein the oligonucleotide inhibits at least 50% of the CD39 expression. The invention is further directed to a pharmaceutical composition comprising such oligonucleotide.
    Type: Application
    Filed: October 9, 2017
    Publication date: July 16, 2020
    Inventors: Frank JASCHINSKI, Tamara THELEMANN
  • Publication number: 20200224203
    Abstract: Described are methods for removing a proteolytic cleavage site, the HCHWA-D mutation or the amino acids encoded by a trinucleotide repeat expansion from a protein comprising providing a cell that expresses pre-mRNA encoding the protein with an anti-sense oligonucleotide that induces skipping of the exonic sequence that comprises the proteolytic cleavage site, HCHWA-D mutation or trinucleotide repeat expansion, respectively, the method further comprising allowing translation of mRNA produced from the pre-mRNA.
    Type: Application
    Filed: February 4, 2020
    Publication date: July 16, 2020
    Inventors: Wilhelmina M.C. van Roon-Mom, Melvin Maurice Evers, Barry Antonius Pepers, Annemieke Aartsma-Rus, Garrit-Jan Boudewijn Van Ommen
  • Publication number: 20200224204
    Abstract: The present disclosure relates to compounds, compositions, and methods for the induction of membraneless organelles.
    Type: Application
    Filed: August 17, 2018
    Publication date: July 16, 2020
    Inventors: Christopher James DONNELLY, Joseph Patrick CLARKE
  • Publication number: 20200224205
    Abstract: The invention relates to virus like particles (VLP) associated with a lysosomal enzyme or an expression vector encoding a lysosomal enzyme which are used in a method for the treatment of a lysosomal storage disease. The invention also relates to a pharmaceutical composition for use in a method for the treatment of a lysosomal storage disease, to an expression vector encoding a lysosomal enzyme and to a method of associating a VLP with an expression vector encoding a lysosomal enzyme.
    Type: Application
    Filed: December 17, 2019
    Publication date: July 16, 2020
    Applicant: NEUWAY Pharma GmbH
    Inventors: Victoria DEMINA, Marcus STAPF, Sergey Sotnikov, Heiko MANNINGA
  • Publication number: 20200224206
    Abstract: Provided herein are non-plasmid derived DNA vaccines comprised solely of enzymatically produced amplicon expression vectors and their method of use to elicit antigen-specific immune responses in a subject. The enzymatically produced amplicon expression vectors may be specifically utilized as a DNA based cancer vaccine to express desired antigens or other immunogenic polypeptides within a subject to induce a specific anti-cancer antigen-specific immune response. The enzymatically produced amplicon expression vectors may also be utilized to express cancer-specific neoantigens.
    Type: Application
    Filed: December 5, 2019
    Publication date: July 16, 2020
    Inventors: Michael E. Hogan, Stephen Hughes, Antonella Conforti, Luigi Aurisicchio, Fabio Palombo
  • Publication number: 20200224207
    Abstract: The present invention provides a method of producing linear or circular DNA by joining two or more types of DNA fragments to each other at regions having homologous base sequences, and a DNA fragment-joining kit used in the method. The present invention provides a DNA production method comprising producing linear or circular DNA by joining the two or more types of DNA fragments to each other at regions having homologous base sequences or regions having complementary base sequences in the reaction solution.
    Type: Application
    Filed: July 5, 2018
    Publication date: July 16, 2020
    Inventors: Masayuki SUETSUGU, Tatsuaki KURATA
  • Publication number: 20200224208
    Abstract: The present disclosure relates to engineered cells that include genetic alterations leading to up- or down-regulation of certain genes in the cells for improved production of a recombinant protein. Also provided are methods of preparing and using such cells.
    Type: Application
    Filed: January 2, 2020
    Publication date: July 16, 2020
    Inventors: Amita Goel, Nikhil Goel
  • Publication number: 20200224209
    Abstract: The present disclosure concerns recombinant microbial host cell having, in glycolytic conditions, increased glycerol importing activity glycerol as well as, in high osmotic conditions, a decreased NAD-dependent glycerol-3-phosphate dehydrogenase (GPD) activity. The recombinant microbial host cell is particularly useful for the fermentation of sugarcane- or molasses-based medium for the production of ethanol.
    Type: Application
    Filed: May 23, 2018
    Publication date: July 16, 2020
    Inventors: Emily Agnes Stonehouse, John Evan Eck McBride, Kristen M. Deleault, Zachary Losordo, Mitchell Codd
  • Publication number: 20200224210
    Abstract: Methods of making haploid plants.
    Type: Application
    Filed: March 29, 2018
    Publication date: July 16, 2020
    Inventor: Arundhati MAHESHWARI
  • Publication number: 20200224211
    Abstract: Transgenic seed for crops with improved traits are provided by trait-improving recombinant DNA in the nucleus of cells of the seed where plants grown from such transgenic seed exhibit one or more improved traits as compared to a control plant. Of particular interest are transgenic plants that have increased yield. The present invention also provides recombinant DNA molecules for expression of a protein, and recombinant DNA molecules for suppression of a protein.
    Type: Application
    Filed: December 20, 2019
    Publication date: July 16, 2020
    Inventors: Mark Scott Abad, Marie Coffin, Barry S. Goldman
  • Publication number: 20200224212
    Abstract: Methods and materials for modulating heat and/or drought tolerance in plants are disclosed. For example, nucleic acids encoding heat and/or drought-tolerance polypeptides are disclosed as well as methods for using such nucleic acids to transform plant cells. Also disclosed are plants having increased heat and/or drought tolerance and plant products produced from plants having increased heat and/or drought tolerance.
    Type: Application
    Filed: February 13, 2020
    Publication date: July 16, 2020
    Inventors: Cory Christensen, Wuyi Wang, Dennis Yang
  • Publication number: 20200224213
    Abstract: The invention provides recombinant DNA molecules and constructs, as well as their nucleotide sequences, useful for modulating gene expression in plants. The invention also provides transgenic plants, plant cells, plant parts, and seeds comprising the recombinant DNA molecules operably linked to heterologous transcribable DNA molecules, as are methods of their use.
    Type: Application
    Filed: January 9, 2020
    Publication date: July 16, 2020
    Inventor: Stanislaw Flasinski
  • Publication number: 20200224214
    Abstract: This disclosure concerns nucleic acid molecules and methods of use thereof for control of insect pests through RNA interference-mediated inhibition of target coding and transcribed non-coding sequences in insect pests, including coleopteran and/or hemipteran pests. The disclosure also concerns methods for making transgenic plants that express nucleic acid molecules useful for the control of insect pests, and the plant cells and plants obtained thereby.
    Type: Application
    Filed: October 7, 2015
    Publication date: July 16, 2020
    Applicant: Dow AgroSciences LLC
    Inventors: Kenneth E. Narva, Huarong Li, Chaoxian Geng, Navin Elango, Marrhew J, Henry, Murugesan Rangasamy, Aaron T. Woosley, Kanika Arora, Premchand Gandra, Sarah E. Worden, Elane Fishilevich
  • Publication number: 20200224215
    Abstract: This disclosure concerns nucleic acid molecules and methods of use thereof for control of insect pests through RNA interference-mediated inhibition of target coding and transcribed non-coding sequences in insect pests, including coleopteran and/or hemipteran pests. The disclosure also concerns methods for making transgenic plants that express nucleic acid molecules useful for the control of insect pests, and the plant cells and plants obtained thereby.
    Type: Application
    Filed: October 7, 2015
    Publication date: July 16, 2020
    Applicant: Dow AgroSciences LLC
    Inventors: Kenneth E. Narva, Huarong Li, Murugesan Rangasamy, Kanika Arora, Premchand Gandra, Sarah E. Worden, Elane Fishilevich
  • Publication number: 20200224216
    Abstract: Compositions and methods for controlling pests are provided. The methods involve transforming organisms with a nucleic acid sequence encoding an insecticidal protein. In particular, the nucleic acid sequences are useful for preparing plants and microorganisms that possess insecticidal activity. Thus, transformed bacteria, plants, plant cells, plant tissues and seeds are provided. Compositions are insecticidal nucleic acids and proteins of bacterial species. The sequences find use in the construction of expression vectors for subsequent transformation into organisms of interest including plants, as probes for the isolation of other homologous (or partially homologous) genes. The pesticidal proteins find use in controlling, inhibiting growth or killing Lepidopteran, Coleopteran, Dipteran, fungal, Hemipteran and nematode pest populations and for producing compositions with insecticidal activity.
    Type: Application
    Filed: January 11, 2018
    Publication date: July 16, 2020
    Applicant: PIONEER HI-BRED INTERNATIONAL, INC.
    Inventors: NURIA JIMENEZ-JUAREZ, ALBERT L LU, LU LIU, MARK EDWARD NELSON, GUSUI WU
  • Publication number: 20200224217
    Abstract: The present disclosure provides a promoter having at least the core components of a duck retinoic acid-inducible gene I (RIG-I) promoter, as well as expression constructs having the duck RIG-I promoter operably linked to a gene product-encoding nucleic acid (e.g., an avian RIG-I protein), and recombinant host cells containing the duck RIG-I promoter, e.g., in such expression constructs. The present disclosure also provide animals genetically modified to have a gene encoding a duck RIG-I promoter operably linked to a gene product-encoding nucleic acid (e.g., an avian RIG-I protein, such as a duck RIG-I protein).
    Type: Application
    Filed: September 28, 2017
    Publication date: July 16, 2020
    Inventors: Katharine MAGOR, Yanna XIAO
  • Publication number: 20200224218
    Abstract: A method is provided to enhance repair or regeneration of a mammalian cardiovascular system to include heart and/or vasculature comprising: administering to a mammal in need thereof a composition comprising an effective amount of an agent that elevates levels of Smo, Ptc1, Shh, Ihh, Dhh, Gli1, Gli2, or Mycn,
    Type: Application
    Filed: July 23, 2019
    Publication date: July 16, 2020
    Inventors: Daniel J. Garry, Mary G. Garry, Bhairab Singh
  • Publication number: 20200224219
    Abstract: In a first aspect, the present invention relates to a mutated adeno-associated virus (AAV) capsid protein or fragment thereof wherein a substitution of a wild type non-cysteine amino acid into a cysteine is present whereby the wild type non-cysteine amino acid is exposed on the outer surface of the capsid of an AAV particle. In a further aspect, a mutated AAV particle comprising the AAV capsid protein or fragment thereof according to the present invention is provided. In addition, a nucleic acid encoding the AAV capsid protein according to the present invention is identified together with a corresponding nucleic acid vector, in particular, a plasmid or a gene string. In addition, a host cell containing the nucleic acid vector or the nucleic acid according to the present invention as well as a composition comprising at least an infectious (transducing) AAV particle containing a mutated AAV capsid protein as defined herein together with a non-infectious AAV particle containing a mutated AAV capsid protein as e.
    Type: Application
    Filed: September 28, 2018
    Publication date: July 16, 2020
    Inventors: Hildegard BÜNING, Anke HUBER, Luca PERABO
  • Publication number: 20200224220
    Abstract: The present disclosure relates to polynucleotides comprising a nucleic acid sequence encoding a replication competent viral genome, wherein the polynucleotide is capable of producing a replication competent virus when introduced into a cell by a non-viral delivery vehicle. The present disclosure further relates to the encapsulation of the polynucleotides and the use of the polynucleotides and/or particles for the treatment and prevention of cancer.
    Type: Application
    Filed: July 13, 2018
    Publication date: July 16, 2020
    Inventors: Mitchell H. FINER, Edward M. KENNEDY, Lorena LERNER
  • Publication number: 20200224221
    Abstract: The present invention relates to the field of genetic engineering. In particular, the present invention relates to a genome editing method with high efficiency and high specificity. More specifically, the present invention relates to a method for increasing the efficiency of site-directed modification of a target sequence in a genome of an organism by a high-specificity Cas9 nuclease variant.
    Type: Application
    Filed: February 22, 2018
    Publication date: July 16, 2020
    Applicant: Institute of Genetics and Developmental Biology, Chinese Academy of Sciences
    Inventors: Caixia GAO, Huawei ZHANG, Dingbo ZHANG